Zynyz (retifanlimab-dlwr) — Medica

Appendiceal cancer

Initial criteria

age ≥ 18 years
ONE of the following: (i) locally unresectable or medically inoperable disease; OR (ii) advanced or metastatic disease; OR (iii) used as neoadjuvant therapy
ONE of the following: (i) deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H); OR (ii) polymerase epsilon/delta (POLE/POLD1) mutation with ultra-hypermutated phenotype (tumor mutational burden > 50 mutations/megabase)
prescribed by or in consultation with an oncologist

1 year